RBC Capital Markets has initiated coverage on IQVIA Holdings Inc. (IQV) with an Outperform rating and a price target of $275. The analyst believes IQVIA’s vast data assets and strong competitive positioning will drive significant earnings growth in the coming years, despite recent headwinds from the COVID-19 pandemic. The company’s unique data collection and expertise in drug development are expected to position it for continued success.
The Factor D complement inhibitor market is poised for significant growth, driven by expanding indications for existing therapies like danicopan and the anticipated approval of novel agents like vemircopan. This market expansion is fueled by advancements in biotechnology, increasing prevalence of autoimmune diseases, and a robust pipeline of drug candidates in clinical trials.
Animal testing is a crucial part of medical research, but its effectiveness is often questioned. A new study reveals a shockingly low success rate of animal-tested therapies in humans, raising concerns about the ethical balance between advancing medicine and animal welfare. The study suggests improvements in animal research methods, along with alternative approaches, could lead to more efficient and ethical research.
The second quarter of 2024 saw a strong performance from several major pharmaceutical companies. Eli Lilly, Pfizer, and AbbVie all exceeded earnings expectations and raised their guidance for the year, driven by the success of new and existing drugs. While the industry faces challenges like generic competition and pricing pressures, these companies’ robust pipelines and innovative products offer promising prospects for future growth.
For the first time, scientists have successfully bred mice with fully functioning human immune systems. These ‘humanized’ mice can accurately mimic human immune responses, opening new avenues for drug development and testing vaccines without relying on human trials.
Despite promising research, many biopharma companies have abandoned genetic therapies for ultra-rare diseases due to limited profit potential. However, Great Ormond Street Hospital in London is taking an unusual step to get a treatment approved on its own.
Thermo Fisher Scientific Inc. (TMO) reported better-than-expected quarterly results and raised its annual profit guidance, citing increasing demand for its products and services in drug development and clinical trials. The company’s laboratory products segment, which contributes over half of its total revenue, saw revenue exceed analysts’ expectations.
The American College of Clinical Pharmacology (ACCP) announced its 2024 annual meeting (#2024ACCP) will take place from September 8 to 10, 2024. The educational and scientific event provides a platform for healthcare professionals and scientists to share knowledge and ideas that drive advancements in healthcare and drug development.
